TreatSMA is looking for a trustee

TreatSMA has grown tremendously over the last year. In a short space of time, with no funds we have established ourselves as serious stakeholders in the decision process. We have/are having a huge input into the outcome of Spinraza. This is ongoing with a member of TreatSMA being elected by NICE as a patient expert to represent the Community voice next month.

We have had newly diagnosed families contacting us now for quite a while. We feel we have played a big part in patients receiving treatment early or putting them forward for participants in trials.

As we grow so does the time needed and costs gathered. We are now looking into turning TreatSMA into a charity.

We have four Trustees who are also four co-founders: Lucy FrostKacper RucinskiGennadiy Ilyashenko and Kelly Jones.

We are looking for a willing person from the Community to be the 5th Founding Trustee.

We would like this person to demonstrate a commitment to SMA. Someone with ideas and the initiative to turn those ideas into actions. Also preferably someone with a history of fundraising and able to start soon. This is an unpaid position. We will reimburse expenses, including in-country travel costs to trustee meetings.

This position will last a year and may then be offered to another person.

If you are interested in this role and have the passion to help change lives please email us at treatsma@treatsma.uk telling us why you see yourself as a TreatSMA trustee. You must to be able to work legally here in the UK.

The Community at www.facebook.com/groups/treatsma.uk will then be given a poll to which they can vote. The other trustees will then speak to the three candidates with the highest community support to select the person to join the team. We are an advocacy group for the Community so it is very important the Community has a say.

This is an exciting time. We believe TreatSMA has a great future and if you would like to be a part of our journey and accomplishments then put your name forward.

Thanks,

– TreatSMA

Latest Posts

  • Calling on all the community to ACT NOW to avoid losing treatments!

    Calling on all the community to ACT NOW to avoid losing treatments!

    Currently, there are two approved treatments for SMA: risdiplam and nusinersen. These treatments were initially approved temporarily under Managed Access Agreements while the NHS and NICE gathered data to assess their cost-effectiveness. Now, as these agreements come to an end, both treatments face a crucial review.

    Read more

  • NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    SMA UK are proud to join together with Treat SMA and MDUK to bring you this webinar about NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam. 2024 sees the end of the managed access agreements (MAAs) for the two treatments. An expert committee will gather to assess the new clinical and real-world evidence, along…

    Read more

  • Let the battle begin

    Let the battle begin

    This year the Managed Access Agreement for Spinraza and Risdiplam expires. The MAA was put in place five years ago so the pharmaceutical companies could gather more evidence to resubmit to NICE for approval on the NHS with Biogen extending their MAA by a year.

    Read more